Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q2 FY23 Earnings Presentation
14 slides from Jagsonpal Pharmaceuticals's earnings presentation, December 2023
Slide 1: Jagsonpal Pharmaceuticals Limited Q2 FY23 Earnings Presentation
Jagsonpal Pharmaceuticals Limited Q2 FY23 Earnings Presentation
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Company Background
JAGSONPAL Company Background
Slide 4: Company Snapshot
Company Snapshot Proven Track Record • Established in 1978, long track record of 40+ years Focus Segments • Specialize in the development & commercialisation of Gynaecology & Orthopaedic focussed products Strong Brands • 17 Brands are among the “Top 5” brands in respective molecule segments Extensiv
Slide 5: Corporate Developments during the quarter
Corporate Developments during the quarter Infinity Holdings acquired 43.73% stake from the Kochhar family, becoming the largest shareholder Infinity Holdings and Kochhar family are joint promoters of the company Established new Board along with induction of eminent Independent Directors Mr. Manish G
Slide 6: Q2 Performance
JAGSONPAL Q2 Performance
Slide 7: Management Commentary
Management Commentary “We are pleased with the strategic direction and financial outcome during Q2FY23, which is the first quarter since the change in ownership structure at promoter level. With a strong focus on key brands, we have been able to achieve a 420-bps improvement in gross margin as well
Slide 8: Q2 FY23 – Ground-work for profitable growth
Q2 FY23 – Ground-work for profitable growth Business o Continuing outperformance on MAT Sep basis - Growth of 14% vis-à-vis industry growth of 7% (Source: IQVIA) o Improved industry ranking by 8 positions - 88th to 80th o Strong performance by Dydrogesterone franchise – collectively 4%+ market share
Slide 9: Key Brands – Yearly Progression basis MAT September
Key Brands – Yearly Progression basis MAT September MAT Sep’22 MAT Sep’21 MAT Sep’22 MAT Sep’21 Molecule Brand Sales Sales Market Share Market Share Hydroxyprogesterone Maintane Inj. 36.82 30.64 25.6% 25.1% Allyeostrenol Maintane Tabs 17.62 17.68 52.7% 52.4% Lycopene Lycored SG 17.58 15.56 4.0% 3.7%
Slide 10: Dydrogesterone – A New Horizon for Jagsonpal
Dydrogesterone – A New Horizon for Jagsonpal o Launch of Dydrogesterone products(DGT) at a competitive price has helped expand the market, replacing the progesterone (NMP) market o DGT market has grown 64% as against 8% for NMP (MAT September 22) o DGT sales have overtaken NMP since September’22 o J
Slide 11: Financial Performance
JAGSONPAL Financial Performance
Slide 12: Profit and Loss Statement
Profit and Loss Statement All values in ₹ lakhs Q2 FY 23 Q1 FY 23 Q2 FY 22 H1 FY 23 H1 FY 22 Particulars Unaudited Unaudited Unaudited Unaudited Unaudited Revenue from Operations 6,052.6 6,059.7 5,839.3 12,112.3 11,244.8 Other Income 112.1 31.4 28.5 143.4 110.7 Total Income 6,164.7 6,091.0 5,867.8 1
Slide 13: Key Balance Sheet Items
Key Balance Sheet Items All value in ₹ lakhs As on As on Particulars th th 30 Sep 30 June Shareholders Funds 13,811 13,699 Tangible Assets 1,869 1,964 Intangible Assets - 3 Net Working Capital 3,247 2,879 Liquid Investments 339 2,439 Cash and cash equivalents 8,061 4,596 13
Slide 14: Thank You
JAGSONPAL Thank You
Jagsonpal Pharmaceuticals — Q2 FY23 Earnings Presentation on 6ix